Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

122.68 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,384
Open	122.68
Bid (Size)	121.80 (100)
Ask (Size)	123.32 (100)
Prev. Close	122.68
Today's Range	122.68 - 122.68
52wk Range	73.31 - 125.14
Shares Outstanding	2,531,374,696
Dividend Yield	2.77%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)

April 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Performance

YTD	+15.2%	+15.2%
1 Month	+4.8%	+4.8%
3 Month	+10.5%	+10.5%
6 Month	+40.2%	+40.2%
1 Year	+49.8%	+49.8%

More News

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Via Finterra

Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗

April 09, 2026

Via Chartmill

Why Terns Pharmaceuticals Stock Rocked the Market in March ↗

April 08, 2026

Via The Motley Fool

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 07, 2026

From Merck & Co., Inc.

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Via The Motley Fool

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

Via MarketMinute

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

Via Finterra

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 01, 2026

From Merck & Co., Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

From Merck & Co., Inc.

Via Business Wire

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

Via The Motley Fool

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

From Merck & Co., Inc.

Via Business Wire

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Via The Motley Fool

2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗

March 26, 2026

Via The Motley Fool

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

Via MarketMinute

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

Via Finterra

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

Via Finterra

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 122.68

When was Merck & Co last traded?

The last trade of Merck & Co was at 04/09/26 07:00 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 310.55B

How many shares of Merck & Co are outstanding?

Merck & Co has 311B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.